Methotrexate: An active drug in bladder cancer
Methotrexate: An active drug in bladder cancer
复制标题
甲氨蝶呤：一种治疗膀胱癌的活性药物
DOI：
10.1002/1097-0142(19810315)47:6
复制
发表时间：
1981
期刊：
影响因子：
6.2
通讯作者：
D. Braun
中科院分区：
文献类型：
--
作者：
R. Natale;A. Yagoda;R. Watson;W. Whitmore;Blumenreich Ms;D. Braun
Forty‐nine patients with transitional urothelial tract tumors received methotrexate: 0.5–1.0 mg/kg I.V. Q W (40 patients) or 250 mg/M2 in a 2‐hour infusion with citrovorum factor rescue 24 hours later (nine patients). Eleven (26%, 95% confidence limits 13–39%) of 42 patients with bidimensionally measurable metastases achieved partial remission. Most responses occurred within 2–3 weeks and persisted for a median duration of six months (range, 2–20). Response rates were increased to 38% (6/16 patients, 95% confidence limits 18–65%) in patients who had no prior chemotherapy, and a 90–100% performance status (50,5/10 patients, 95% confidence limits 22–78%) compared with 19% (5/26, 95% confidence limits 8–37%) in patients who had prior chemotherapy and a ≦80% performance status (19%, 6/32 cases, 95% confidence limits 9–32%). Toxicity included mucositis and myelosuppression. A review of the literature coupled with the present data suggest that methotrexate is as active as cisplatin in the treatment of patients with advanced urinary bladder cancer.
